Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jaguar Animal Health ( (JAGX) ) has provided an update.
On May 19, 2026, Jaguar Health entered into privately negotiated exchange agreements with Uptown Capital and Streeterville Capital, issuing a total of 908 shares of new Series Q Perpetual Preferred Stock in exchange for a combined $22.7 million reduction in royalty interest obligations originating from 2020 and 2022 financings. The move reduces Jaguar’s royalty debt burden while granting these investors significant preferred rights tied to company governance, liquidation preference and future equity issuance constraints.
The Series Q Preferred Stock, authorized up to 2,000 shares, carries a 10% annual preferred return payable in additional Series Q shares, has no dividend entitlement, and is generally non-convertible but can be exchanged into common stock at the company’s option subject to ownership caps, trading, and Nasdaq-related limits. Extensive covenants and default remedies give holders strong protections, including consent rights over major corporate actions, limits on new equity and indebtedness changes, and the ability to force redemption in common stock upon an event of default, which may affect Jaguar’s strategic flexibility and existing shareholders’ potential dilution and voting dynamics.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.
The score is pressured primarily by weak financial quality (large ongoing losses and a stressed balance sheet) and very bearish technicals (price far below key moving averages with negative MACD and extremely low RSI). Corporate events add meaningful listing-compliance risk despite some positive financing and debt restructuring, while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of prescription medicines derived from plant-based compounds. The company’s products and pipeline target gastrointestinal conditions and related disorders, with a market focus on both human and animal health segments in specialty and niche therapeutic areas.
Average Trading Volume: 43,026
Technical Sentiment Signal: Sell
Current Market Cap: $1.57M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.